Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

eXoZymes Inc. - Common Stock (NQ:EXOZ)

7.200 +0.250 (+3.60%)
Streaming Delayed Price Updated: 11:48 AM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,807
Open 7.180
Bid (Size) 6.450 (100)
Ask (Size) 7.720 (100)
Prev. Close 6.950
Today's Range 6.450 - 7.680
52wk Range 4.350 - 18.40
Shares Outstanding 8,387,250
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Investor Summit | MicroCap Opportunities to Watch - August 26
From Investor Summit Group
Via ACCESS Newswire
News headline image
eXoZymes Q2 Earnings Call Highlights ↗
eXoZymes (NASDAQ:EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it... 
Via MarketBeat
Topics Earnings

Performance

YTD
-34.5%
-34.5%
1 Month
+58.2%
+58.2%
3 Month
-27.3%
-27.3%
6 Month
-16.8%
-16.8%
1 Year
-25.8%
-25.8%

More News

Read More
News headline image
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
Via ACCESS Newswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
Via Benzinga
News headline image
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
From eXoZymes
Via ACCESS Newswire
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
From Investor Summit Group
Via ACCESS Newswire
News headline image
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Inc. Announces Closing of $6 Million Public Offering
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Via ACCESS Newswire
News headline image
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
Via ACCESS Newswire
News headline image
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
Via ACCESS Newswire
News headline image
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Via ACCESS Newswire
News headline image
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
Via ACCESS Newswire
News headline image
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
Via ACCESS Newswire
News headline image
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
Via ACCESS Newswire
News headline image
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
Via ACCESS Newswire
News headline image
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
Via ACCESS Newswire
News headline image
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
Via ACCESS Newswire
News headline image
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
Via ACCESS Newswire
News headline image
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
Via ACCESS Newswire

Frequently Asked Questions

Is eXoZymes Inc. - Common Stock publicly traded?
Yes, eXoZymes Inc. - Common Stock is publicly traded.
What exchange does eXoZymes Inc. - Common Stock trade on?
eXoZymes Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for eXoZymes Inc. - Common Stock?
The ticker symbol for eXoZymes Inc. - Common Stock is EXOZ on the Nasdaq Stock Market
What is the current price of eXoZymes Inc. - Common Stock?
The current price of eXoZymes Inc. - Common Stock is 7.200
When was eXoZymes Inc. - Common Stock last traded?
The last trade of eXoZymes Inc. - Common Stock was at 08/25/26 11:48 AM ET
What is the market capitalization of eXoZymes Inc. - Common Stock?
The market capitalization of eXoZymes Inc. - Common Stock is 60.39M
How many shares of eXoZymes Inc. - Common Stock are outstanding?
eXoZymes Inc. - Common Stock has 60M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.